For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 15,166 | 14,988* | 13,648 | 16,182 |
| General and administrative | 4,736 | 5,365* | 6,039 | 6,467 |
| Total operating expenses | 19,902 | 20,353 | 19,687 | 22,649 |
| Loss from operations | -19,902 | -20,353* | -19,687 | -22,649 |
| Interest income | 989 | 1,625* | 1,506 | 1,730 |
| Other expense, net | -129 | -60* | -53 | -87 |
| Total other income, net | 860 | 1,565* | 1,453 | 1,643 |
| Net loss | -19,042 | -18,788 | -18,234 | -21,006 |
| Unrealized gain (loss) on available-for-sale investments, net of tax | - | - | 6 | -177 |
| Comprehensive loss | - | - | -18,228 | -21,183 |
| Basic EPS | -0.49 | -0.488 | -0.47 | -0.55 |
| Diluted EPS | -0.49 | -0.488 | -0.47 | -0.55 |
| Basic Average Shares | 38,724,803 | 38,505,760 | 38,560,464 | 38,461,619 |
| Diluted Average Shares | 38,724,803 | 38,505,760 | 38,560,464 | 38,461,619 |
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)